| dc.contributor.author | Lizbeth A Manzanares-Guevara | |
| dc.contributor.author | Jahaziel Gasperin-Bulbarela | |
| dc.contributor.author | Olivia Cabanillas-Bernal | |
| dc.contributor.author | Monserrat Renteria-Maciel | |
| dc.contributor.author | Angel Licea-Claverie | |
| dc.contributor.author | Eugenio R Méndez | |
| dc.contributor.author | Alexei F Licea-Navarro | |
| dc.date.accessioned | 2024-01-23T05:30:50Z | |
| dc.date.accessioned | 2025-10-08T09:01:28Z | |
| dc.date.available | 2025-10-08T09:01:28Z | |
| dc.date.issued | 01-00-2024 | |
| dc.identifier.uri | http://digilib.fisipol.ugm.ac.id/repo/handle/15717717/38622 | |
| dc.description.abstract | Cancer is the second leading cause of death worldwide. To combat this disease, novel and specialized therapeutic systems are urgently needed. This is the first study to explore a system that combines shark variable domain (Fv) of new antigen receptor (VNAR) antibodies (hereinafter VNARs), PEGylated nanogels (pH-sensitive poly(N,N-diethylaminoethyl methacrylate, PDEAEM), and the anticancer drug 5-fluorouracil (5-FU) to explore its potential applications in colon cancer therapies. Nanogels were functionalized in a scalable reaction with an N-hydroxysuccinimide (NHS)-terminated polyethylene glycol derivative and bioconjugated with shark antibodies. Dynamic light scattering measurements indicated the presence of monodispersed nanogels (74 to 236 nm). All systems maintained the pH-sensitive capacity to increase in size as pH decreased. This has direct implications for the release kinetics of 5-FU, which was released faster at pH 5 than at pH 7.4. After bioconjugation, the ELISA results indicated VNAR presence and carcinoembryonic antigen (CEA) recognition. In vitro evaluations of HCT-116 colon cancer cells indicated that functionalized empty nanogels are not cytotoxic and when loaded with 5-FU, the cytotoxic effect of the drug is preserved. A 15% reduction in cell viability was observed after two hours of contact with bioconjugated nanogels when compared to what was observed with non-bioconjugated nanogels. The prepared nanogel system shows potential as an effective and site-specific nanocarrier with promising applications in in vivo studies of colon cancer therapies. | |
| dc.language.iso | EN | |
| dc.publisher | Public Library of Science (PLoS) | |
| dc.subject.lcc | Medicine | |
| dc.title | Preparation of pH-sensitive nanogels bioconjugated with shark antibodies (VNAR) for targeted drug delivery with potential applications in colon cancer therapies. | |
| dc.type | Article | |
| dc.description.doi | 10.1371/journal.pone.0294874 | |
| dc.title.journal | PLoS ONE | |
| dc.identifier.e-issn | 1932-6203 | |
| dc.identifier.oai | oai:doaj.org/journal:9b5e30aa781545fd9e2a91939f0f7374 | |
| dc.journal.info | Volume 19, Issue 1 | |
